Moderna, Inc.

Pharmaceuticals, Biotechnology and Life Sciences

Targets set1.5°CNet-Zero: Targets set

SBTI ID

40008085

Informations générales

Localisation

United States of America

Northern America

Secteur d'activité

Pharmaceuticals, Biotechnology and Life Sciences

Type d'organisation

Corporate

Dernière mise à jour

09/01/2025

Objectifs à court terme (Near-Term)
Engagement de réduction des émissions à horizon 2030

Statut

Targets set

Classification

1.5°C

Année cible

2030

Progression vers l'objectif73%
2015 (année de référence)2030
Objectifs à long terme (Long-Term)
Engagement de réduction des émissions à horizon 2045

Statut

Targets set

Classification

1.5°C

Année cible

2045

Progression vers l'objectif37%
2015 (année de référence)2045
Description complète des objectifs

Overall Net-Zero Target: Moderna, Inc. commits to reach net-zero greenhouse gas emissions across the value chain by 2045. Near-Term Targets: Moderna, Inc. commits to reduce absolute scope 1 and 2 GHG emissions 90% by 2030 from a 2021 base year. Moderna, Inc. commits that 85% of its suppliers by emissions covering purchased goods and services, capital goods and upstream transportation and distribution, will have science-based targets by 2028. Long-Term Targets: Moderna, Inc. commits to maintain a minimum of 90% absolute scopes 1 and 2 GHG emissions from 2030 through 2045 from a 2021 base year. Moderna, Inc. also commits to reduce absolute scope 3 GHG emissions emissions 90% by 2045 from a 2021 base year.

Net-Zero

Statut

Targets set

Année cible

2045

Progression37%
Business Ambition 1.5°C

Statut

BA1.5 member

Date d'engagement

16/06/2022

Classification détaillée

The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C

Identifiants

ISIN

US60770K1079

LEI

549300EI6OKH5K5Q2G38

Source : Science Based Targets initiative | Données publiques